Jerry, As much as I'd like to believe that animal results (stroke recovery data) for high impacts will produce a near term broad deal or buyout, it doesn't seem very likely. Not only don't we have high impact POC in humans, we don't even have Phase 1 safety data yet in humans. And I think Cortex just recently axed some of the high impact / neurodegeneration arm as a cost saving measure as part of the restructuring.
Maybe Neuro will chime in here, but I'm skeptical about seeing very much in upfronts by partnering away the high impacts at this early stage.
Cortex often brings out some high impact info when there's a lull in other activity. In the recent Amex delisting press release, they put in a blurb about animal data for CX-1837 in stroke recovery, and some CX-929 mouse data that might relate to bipolar disorder. I was kind of surprised to see these mentions, and considered them a somewhat lame attempt at spin by Cortex's public relations outfit.
Would love to be wrong though. If Neuro's out there, perhaps he can give some idea on what the high impacts might bring currently in a partnership. I would hate to see the high impacts sold off on the cheap, and in some ways, Enemem's plan to sell off the low impact platform and keep the high impacts inhouse might make more sense, though that would also be a shame. I figure if SA bombs, they'll just sell the entire company whole.
News 
Market Data 
Discover 
AI
